Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients

Objectives: This retrospective study included 21 patients with primary osteoporosis who were treated with the anti-resorption drug, denosumab. To date, there has been no detailed report on the changes of bone-related minerals after anti-resorption drug therapy. Methods: Twenty-one post-menopausal fe...

Full description

Bibliographic Details
Main Authors: Takako Suzuki, Yukio Nakamura, Hiroyuki Kato
Format: Article
Language:English
Published: MDPI AG 2017-08-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/9/8/871
id doaj-6b50c54aeced417a8d103391160882f6
record_format Article
spelling doaj-6b50c54aeced417a8d103391160882f62020-11-25T00:09:23ZengMDPI AGNutrients2072-66432017-08-019887110.3390/nu9080871nu9080871Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic PatientsTakako Suzuki0Yukio Nakamura1Hiroyuki Kato2Department of Orthopedic Surgery, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, JapanDepartment of Orthopedic Surgery, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, JapanDepartment of Orthopedic Surgery, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, JapanObjectives: This retrospective study included 21 patients with primary osteoporosis who were treated with the anti-resorption drug, denosumab. To date, there has been no detailed report on the changes of bone-related minerals after anti-resorption drug therapy. Methods: Twenty-one post-menopausal females were retrospectively enrolled. Serum zinc (Zn), magnesium (Mg), iron (Fe), copper (Cu), grip strength, and estimated glomerular filtration rate (eGFR) were examined at one week and 1, 2, 4, 6, 8, 10, and 12 months. Lumbar spine (L1-4) bone mineral density (L-BMD) and bilateral total hip BMD (H-BMD) were examined before and at 4, 8, and 12 months after treatment commencement. Results: Serum Zn tended to decrease at one week and one month, and tended to increase during 10 to 12 months. Serum Cu maintained during zero to eight months, then decreased at 10 and 12 months. Serum Fe gradually increased after four months. Serum Mg sharply increased at one week, then decreased further. Grip strength increased for two months, then slightly decreased and maintained 4 to 12 months. eGFR almost maintained for zero to eight months, then slightly decreased thereafter. L-BMD values significantly increased at eight (5.8%) (p < 0.01) and 12 months (9.8%) (p < 0.01). H-BMD increased during the period (at 12 months: 3.7%). Conclusions: These results suggest that at later phases of denosumab therapy, Zn and Fe tended to increase while Mg tended to decrease, all of which are important for bone metabolism. Thus, denosumab might improve Zn and Fe metabolism, and thereby likely increase BMD. Since denosumab may not improve Mg, it is better to obtain Mg supplementation during the therapy.https://www.mdpi.com/2072-6643/9/8/871bone mineral densitybone-related mineralsdenosumabosteoporosis
collection DOAJ
language English
format Article
sources DOAJ
author Takako Suzuki
Yukio Nakamura
Hiroyuki Kato
spellingShingle Takako Suzuki
Yukio Nakamura
Hiroyuki Kato
Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
Nutrients
bone mineral density
bone-related minerals
denosumab
osteoporosis
author_facet Takako Suzuki
Yukio Nakamura
Hiroyuki Kato
author_sort Takako Suzuki
title Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
title_short Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
title_full Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
title_fullStr Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
title_full_unstemmed Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
title_sort changes of bone-related minerals during denosumab administration in post-menopausal osteoporotic patients
publisher MDPI AG
series Nutrients
issn 2072-6643
publishDate 2017-08-01
description Objectives: This retrospective study included 21 patients with primary osteoporosis who were treated with the anti-resorption drug, denosumab. To date, there has been no detailed report on the changes of bone-related minerals after anti-resorption drug therapy. Methods: Twenty-one post-menopausal females were retrospectively enrolled. Serum zinc (Zn), magnesium (Mg), iron (Fe), copper (Cu), grip strength, and estimated glomerular filtration rate (eGFR) were examined at one week and 1, 2, 4, 6, 8, 10, and 12 months. Lumbar spine (L1-4) bone mineral density (L-BMD) and bilateral total hip BMD (H-BMD) were examined before and at 4, 8, and 12 months after treatment commencement. Results: Serum Zn tended to decrease at one week and one month, and tended to increase during 10 to 12 months. Serum Cu maintained during zero to eight months, then decreased at 10 and 12 months. Serum Fe gradually increased after four months. Serum Mg sharply increased at one week, then decreased further. Grip strength increased for two months, then slightly decreased and maintained 4 to 12 months. eGFR almost maintained for zero to eight months, then slightly decreased thereafter. L-BMD values significantly increased at eight (5.8%) (p < 0.01) and 12 months (9.8%) (p < 0.01). H-BMD increased during the period (at 12 months: 3.7%). Conclusions: These results suggest that at later phases of denosumab therapy, Zn and Fe tended to increase while Mg tended to decrease, all of which are important for bone metabolism. Thus, denosumab might improve Zn and Fe metabolism, and thereby likely increase BMD. Since denosumab may not improve Mg, it is better to obtain Mg supplementation during the therapy.
topic bone mineral density
bone-related minerals
denosumab
osteoporosis
url https://www.mdpi.com/2072-6643/9/8/871
work_keys_str_mv AT takakosuzuki changesofbonerelatedmineralsduringdenosumabadministrationinpostmenopausalosteoporoticpatients
AT yukionakamura changesofbonerelatedmineralsduringdenosumabadministrationinpostmenopausalosteoporoticpatients
AT hiroyukikato changesofbonerelatedmineralsduringdenosumabadministrationinpostmenopausalosteoporoticpatients
_version_ 1725412190167498752